1CP
ABBV icon

17 Capital Partners’s AbbVie ABBV Stock Holding History

17 Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$278K Buy
1,276
+227
+22% +$50.4K 0.14% 158
2025
Q4 		$240K Sell
1,049
-29
-3% -$6.61K 0.12% 151
2025
Q3 		$250K Sell
1,078
-2
-0.2% -$407 0.14% 135
2025
Q2 		$200K Sell
1,080
-17
-2% -$3.16K 0.12% 142
2025
Q1 		$230K Buy
+1,097
New +$213K 0.15% 131
2024
Q4 		– Sell
-1,072
Closed -$212K – 135
2024
Q3 		$212K Buy
+1,072
New +$200K 0.14% 128

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

17 Capital Partners's ABBV Position: Q1 2026 in Review

17 Capital Partners increased its AbbVie (ABBV) stake by 22% in Q1 2026, buying an estimated $50.4K and bringing the position to 1,276 shares worth $278K. The position accounts for 0.14% of the portfolio, ranked #158.

17 Capital Partners first reported a position in ABBV in Q3 2024 and has held it in 6 quarters since. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • 17 Capital Partners held 1,276 shares of AbbVie worth $278K as of Q1 2026.
  • 17 Capital Partners bought 227 AbbVie shares in Q1 2026, an estimated $50.4K.
  • AbbVie made up 0.14% of 17 Capital Partners's portfolio in Q1 2026, its #158 holding.
  • 17 Capital Partners first reported a position in AbbVie in Q3 2024 and has held it in 6 quarters since.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on 17 Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.